Display options
Cite
Pagliarulo V, Ancona P, Martines I, et al. Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol. 2015;7(6):303-11doi: 10.1177/1756287215599695.
Pagliarulo, V., Ancona, P., Martines, I., Spadavecchia, R., Di Stasi, S., Alba, S., Cormio, L., Fanizza, C., Salerno, A., Carrieri, G., & Pagliarulo, A. (2015). Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Therapeutic advances in urology, 7(6), 303-11. https://doi.org/10.1177/1756287215599695
Pagliarulo, Vincenzo, et al. "Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study." Therapeutic advances in urology vol. 7,6 (2015): 303-11. doi: https://doi.org/10.1177/1756287215599695
Pagliarulo V, Ancona P, Martines I, Spadavecchia R, Di Stasi S, Alba S, Cormio L, Fanizza C, Salerno A, Carrieri G, Pagliarulo A. Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol. 2015 Dec;7(6):303-11. doi: 10.1177/1756287215599695. PMID: 26622316; PMCID: PMC4647141.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Urol. 2015 Dec;7(6):303-11. doi: 10.1177/1756287215599695.

Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.

Therapeutic advances in urology

Vincenzo Pagliarulo, Patrizia Ancona, Ivan Martines, Rossana Spadavecchia, Savino Di Stasi, Stefano Alba, Luigi Cormio, Caterina Fanizza, Annamaria Salerno, Giuseppe Carrieri, Arcangelo Pagliarulo

Affiliations

  1. Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy.
  2. Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
  3. Department of Surgery/Urology, Tor Vergata University, Rome, Italy.
  4. Department of Urology and Renal Transplantation, University of Foggia, Italy.
  5. Department of Clinical Pharmacology and Epidemiology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Italy.
  6. Department of Urology, University Hospital Campus Bio-Medico, Rome, Italy.

PMID: 26622316 PMCID: PMC4647141 DOI: 10.1177/1756287215599695

Abstract

OBJECTIVES: New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in vitro and in vivo models of bladder cancer. Therefore, we conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC.

METHODS: Treatment with celecoxib was administered orally for 12 months and compared with a contemporary series of patients treated with intravesical mitomycin C (MMC), given weekly for 4 weeks and then monthly for 11 months. Primary endpoints were time to first recurrence and adverse events.

RESULTS: From 2003 through 2006, 58 patients were treated with celecoxib and compared with 66 patients receiving MMC. After a median follow up of 75 months, 49 patients were disease free, including 23 (34.85%) in the MMC group and 26 (44.8%) in the celecoxib group. Median disease-free interval was 67 months [95% confidence interval (CI) 35.8 to NA] versus 41 months (95% CI 27.1-67.1; log-rank p = 0.25) for patients treated with MMC and celecoxib, respectively. In the multivariate analysis, treatment was not found to be an independent predictor for recurrence [hazard ratio (HR) 0.76, 95% CI 0.47-1.22, p = 0.25). Overall, 45 AEs were recorded in 35/124 patients. There were no differences between the two groups.

CONCLUSIONS: Our data support a clinical benefit of celecoxib and encourage future trials in which COX-2 inhibitors may be tested in selected patients with NMIBC.

Keywords: bladder cancer; celecoxib; cyclooxygenase; recurrence; treatment

References

  1. Mol Cancer. 2013 May 24;12 :47 - PubMed
  2. Eur Urol. 2008 Jan;53(1):45-52 - PubMed
  3. J Clin Oncol. 1994 Jan;12(1):1-4 - PubMed
  4. Cancer Res. 2005 Mar 1;65(5):1808-13 - PubMed
  5. Eur Urol. 2008 Sep;54(3):621-30 - PubMed
  6. Eur Urol. 2008 Apr;53(4):709-19 - PubMed
  7. J Urol. 1999 Apr;161(4):1124-7 - PubMed
  8. Eur Urol. 2004 Jun;45(6):730-5; discussion 735-6 - PubMed
  9. Cancer Prev Res (Phila). 2011 Oct;4(10):1580-9 - PubMed
  10. Gut. 2002 Jun;50(6):857-60 - PubMed
  11. J Urol. 2005 Jan;173(1):56-60 - PubMed
  12. J Urol. 2006 Jun;175(6):2004-10 - PubMed
  13. BJU Int. 2001 Aug;88(3):209-16 - PubMed
  14. N Engl J Med. 2006 Aug 31;355(9):885-95 - PubMed
  15. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7 - PubMed
  16. N Engl J Med. 2006 Aug 31;355(9):873-84 - PubMed
  17. N Engl J Med. 2000 Jun 29;342(26):1946-52 - PubMed
  18. J Urol. 2006 Nov;176(5):1914-20 - PubMed
  19. Eur Urol. 2013 Mar;63(3):462-72 - PubMed
  20. J Urol. 2003 Mar;169(3):938-42 - PubMed
  21. Cancer Res. 2000 Oct 15;60(20):5599-602 - PubMed
  22. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528 - PubMed
  23. J Urol. 2006 Sep;176(3):935-9 - PubMed
  24. Eur Urol. 2009 Sep;56(3):430-42 - PubMed
  25. Am J Pathol. 2001 Mar;158(3):849-53 - PubMed
  26. N Engl J Med. 2005 Mar 17;352(11):1071-80 - PubMed

Publication Types